

Hep B Consult: A Point-of-Care Interactive Decision Support Tool Delivers Real-Time, Personalized, HBV Guideline-Based Teaching

Zachary Schwartz, MSc, ELS*; Jenny Schulz, PhD*; Jennifer M. Blanchette, PhD*; Edward King, MA*; Kosh Agarwal, MD†; Grace L. Wong, MD‡, Paul Y. Kwo, MD§


*Clinical Care Options, LLC. †Institute of Liver Studies, King's College Hospital NHS Trust. ‡Institute of Digestive Disease, Department of Medicine and Therapeutics, The Chinese University of Hong Kong. §Stanford University School of Medicine.

1. Background

- We previously identified variance in HBV management strategies between community clinicians and experts^[1]
- Here, we developed a comprehensive online decision support tool based on **American, European, and Asian Pacific guideline recommendations**
- Tool is available as an app and on the CCO Web site

2. Participant Demographics

- From March through October 2019, **N = 3371** participants entered cases into the tool
 - n = 2470 participants via the app (anonymous)
 - n = 901 participants via the CCO site (authenticated)



3. Cases Entered




- Of 2478 cases where participants specified:
- 55% were real patients
 - 45% were hypothetical cases

- In **28%** of all cases, participants selected a management plan without knowing one of the following factors:
 - HBeAg status
 - ALT and HBV DNA
 - Liver histology/fibrosis
 - Extrahepatic manifestations
 - Bone or renal disease
 - Other comorbidities
- In these cases, the tool provided education on why these patient characteristics are needed before deciding how to manage the patient

4. Online Decision Support Tool Provides Patient-Specific Recommendations


- Participant enters patient and disease characteristics
- Participant indicates management plan
- Participant receives guideline recommendations for that specific case
- Participant is asked if guideline recommendations changed their management plan

5. Baseline Management Plan



6. Posteducation Impact

Subset of Clinician Cases Where Baseline Plan Differed From Guidelines and Clinician Identified Future Plan



7. Conclusions

- This online decision support tool showed that clinicians' initial HBV management plans of whether to treat and what to treat with **differed from guidelines** for 43% of case scenarios
- Using an online tool **changed the intended treatment plan for many participants**, suggesting the tool's use can help optimize care of patients with chronic HBV infection

Reference: 1. Schwartz. AASLD 2018. Poster 406. https://www.clinicalcareoptions.com/publications/2018/11_2018_san_francisco_hbv_poster

Disclosures: *None. †Funds for research support from Gilead Sciences and Merck Sharp & Dohme; consulting fees from Arbutus, Gilead Sciences, and Vir Biotechnology. ‡Consulting fees from AbbVie, Arrowhead, Bristol-Myers Squibb, Gilead Sciences, and Quest; funds for research support from Assembly, Bristol-Myers Squibb, and Gilead Sciences; served on a data and safety monitoring board for Johnson & Johnson. §Consulting fees from Gilead Sciences and Janssen; funds for research support from Gilead Sciences; speaker bureaus for Abbott, AbbVie, Bristol-Myers Squibb, Echoscience, Furui, Gilead Sciences, Janssen, and Roche.

Acknowledgements: This research is based on CME activities supported by an independent educational grant from Gilead Sciences.